Skip to Content

Enasidenib

In the US, Enasidenib (enasidenib systemic) is a member of the drug class miscellaneous antineoplastics and is used to treat Acute Myeloid Leukemia.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01XX

CAS registry number (Chemical Abstracts Service)

1446502-11-9

Chemical Formula

C19-H17-F6-N7-O

Molecular Weight

473

Chemical Name

2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol (WHO)

Foreign Names

  • Enasidenibum (Latin)
  • Enasidenib (German)
  • Enasidénib (French)
  • Enasidenib (Spanish)

Generic Names

  • Enasidenib (OS: WHO)
  • AG-221 (ChemID) (IS)
  • CC-90007 Free Base (ChemID) (IS)
  • UNII-3T1SS4E7AG (ChemID) (IS)
  • Enasidenib Mesylate (OS: USAN)
  • AG-221 mesylate (ChemID) (IS)
  • CC-90007 (ChemID) (IS)
  • UNII-UF6PC17XAV (ChemID) (IS)

Brand Name

  • Idhifa
    Celgene, United States

Glossary

TermDefinition
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide